Want to see HK:1061 full AI Analyst Report?
1061 Stock Chart & Stats
HK$2.24
-HK$0.03(-1.21%)
At close: 4:00 PM EDT
HK$2.24
-HK$0.03(-1.21%)
Day’s Range― - ―
52-Week RangeHK$2.01 - HK$5.33
Previous CloseN/A
Volume51.00K
Average Volume (3M)299.59K
Market Cap
HK$1.24B
Enterprise ValueHK$1.06K
Total Cash (Recent Filing)HK$807.73M
Total Debt (Recent Filing)HK$348.99M
Price to Earnings (P/E)4.6
Beta0.56
Next Earnings
Mar 11, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.49%
Share Statistics
EPS (TTM)0.47
Shares Outstanding567,006,000
10 Day Avg. Volume248,810
30 Day Avg. Volume299,591
Financial Highlights & Ratios
PEG Ratio1.82
Price to Book (P/B)0.89
Price to Sales (P/S)1.18
P/FCF Ratio16.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.57
Revenue Forecast (FY)HK$1.87B
Bulls Say, Bears Say
Bulls Say
Exceptional Gross MarginsExceptionally high and stable gross margins indicate strong product economics and provide meaningful room to absorb operating costs. Their consistency across multiple periods supports durable profitability and gives Essex flexibility to fund commercialization, research, and other strategic priorities.
Improving Balance SheetThe sustained reduction in leverage strengthens financial resilience and lowers dependence on external financing. A conservative balance sheet gives Essex greater capacity to withstand operating volatility, continue investment, and preserve strategic flexibility over the next several quarters.
Strong Returns On EquityConsistently strong returns on equity indicate that the company has been using its capital productively despite uneven revenue trends. This supports the quality of the underlying business model and suggests that retained capital can continue generating attractive operating returns.
Bears Say
Choppy Revenue GrowthUneven revenue performance points to inconsistent demand or commercialization momentum, making future earnings less predictable. A modest recovery after prior declines does not yet establish a durable growth trajectory, which could constrain operating leverage and longer-term expansion.
Volatile Free Cash FlowThe sharp decline in free cash flow reduces the reliability of cash conversion relative to reported earnings. If volatility persists, Essex may have less internally generated cash available for reinvestment and shareholder returns, increasing execution pressure around capital allocation.
Profitability NormalizationAlthough profitability remains solid, the decline in net margin from earlier peak levels signals some normalization in earnings quality or operating efficiency. Further margin pressure would reduce the benefit of the company’s strong gross economics and could limit earnings growth even if revenue improves.
Essex Bio-Technology News
1061 FAQ
What was Essex Bio-Technology Limited’s price range in the past 12 months?
Essex Bio-Technology Limited lowest stock price was HK$2.01 and its highest was HK$5.33 in the past 12 months.
What is Essex Bio-Technology Limited’s market cap?
Essex Bio-Technology Limited’s market cap is HK$1.24B.
When is Essex Bio-Technology Limited’s upcoming earnings report date?
Essex Bio-Technology Limited’s upcoming earnings report date is Mar 11, 2027 which is in 162 days.
How were Essex Bio-Technology Limited’s earnings last quarter?
Essex Bio-Technology Limited released its earnings results on Aug 05, 2026. The company reported HK$0.195 earnings per share for the quarter.
Is Essex Bio-Technology Limited overvalued?
According to Wall Street analysts Essex Bio-Technology Limited’s price is currently Overvalued.
Does Essex Bio-Technology Limited pay dividends?
Essex Bio-Technology Limited pays a Semiannually dividend of HK$0.05 which represents an annual dividend yield of 5.49%. See more information on Essex Bio-Technology Limited dividends here
What is Essex Bio-Technology Limited’s EPS estimate?
Essex Bio-Technology Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Essex Bio-Technology Limited have?
Essex Bio-Technology Limited has 567,006,000 shares outstanding.
What happened to Essex Bio-Technology Limited’s price movement after its last earnings report?
Essex Bio-Technology Limited reported an EPS of HK$0.195 in its last earnings report. Following the earnings report the stock price went down -1.657%.
Which hedge fund is a major shareholder of Essex Bio-Technology Limited?
Currently, no hedge funds are holding shares in HK:1061
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Essex Bio-Technology Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.99%
12-Months-Change
Fundamentals
Return on Equity
5.49%
Trailing 12-Months
Asset Growth
11.82%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Essex Bio-Technology Limited
Essex Bio-Technology Limited operates as an investment holding company, specializing in the development, manufacturing, distribution, and sale of biopharmaceutical products. Its business activities extend across the People's Republic of China and into international territories. The company organizes its operations into two primary segments: Ophthalmic Products and Surgical Products. A significant focus of its research and development is on basic fibroblast growth factor (bFGF) products, which are utilized to promote cellular proliferation, differentiation, and migration. Its ophthalmic offerings include the Beifushu series, comprising eye drops, eye gel, and unit-dose eye drops. Other eye care solutions feature Tobramycin eye drops, Levofloxacin eye drops, Sodium Hyaluronate eye drops, and Iodized Lecithin Capsules. For surgical and wound care needs, the company supplies Beifuji sprays and lyophilized powder, along with Beifuxin gels. These are applied in cases of burns, scalds, acute wounds, surgical incisions, chronic wounds, and skin grafting, among other uses. In addition to its proprietary innovations, Essex Bio-Technology distributes ophthalmic and surgical products sourced from third-party manufacturers. Its diverse product portfolio also encompasses Carisolv dental caries removal gel and Yi Xue An Granules. The company holds licensing agreements with both Mitotech S.A. and Mitotech LLC. Founded in 1990, Essex Bio-Technology Limited maintains its headquarters in Zhuhai, China.
Technical Analysis
Hua Medicine
―
Lee's Pharmaceutical Holdings Limited
―
Dawnrays Pharmaceutical Holdings Ltd.
―
Jacobson Pharma Corporation Limited
―
VISEN Pharmaceuticals
―